Does size matter? A comparison of 70-150 μm (M1) versus 100-300 μm drug-eluting beads in transarterial chemoembolization for hepatic malignancy

Heckman, Alexander; DeFoe, A.; Donovan, Tim; Vargo, Christopher

doi:10.1016/j.jvir.2015.12.225

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 There have only been a few studies comparing tumour response and safety of 70-150 lm vs. 100-300 lm DEB particles. 15,16 Our study demonstrates DEB-TACE with 70-150 lm had significantly better 1-month mRECIST overall response rate (CR + PR) compared to 100-300 lm (96.2% vs. 61.9%). Patients treated with 70-150 lm DEB particles were significantly less likely to have progressive disease on 1-month follow-up tumour imaging compared those treated with 100-300 lm DEB sizes (3.8% vs. 33.3%, odds ratio 7.15, P = 0.007).…”

Section: Discussionmentioning

confidence: 71%

“…However, a recent single‐arm study by Aliberti et al with 70–150 μm sized DEB has shown impressive overall response rates and median overall survival of 42 months . There have only been a few studies comparing tumour response and safety of 70–150 μm vs. 100–300 μm DEB particles …”

Section: Discussionmentioning

confidence: 99%

“…More recently, 70–150 μm sized DEB has shown impressive overall response rates of 99.5% at 6 months with a median overall survival of 42.0 months . There have been few small retrospective studies in the literature, which have compared the outcomes of 70–150 μm vs. 100–300 μm DEB particles …”

Section: Introductionmentioning

confidence: 99%

“…14 There have been few small retrospective studies in the literature, which have compared the outcomes of 70-150 lm vs. 100-300 lm DEB particles. 15,16 The purpose of this study is to assess the efficacy and safety of DEB-TACE for patients treated with 70-150 lm compared to 100-300 lm DEB particles, as well as identify prognostic risk factors for survival and progressionfree survival for DEB-TACE.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survival, tumour response and safety of 70‐150 μm versus 100‐300 μm doxorubicin drug‐eluting beads in transarterial chemoembolisation for hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

Introduction This study investigates the outcomes and safety of 70–150 μm and 100–300 μm doxorubicin drug‐eluting bead transarterial chemoembolisation (DEB‐TACE) in patients with unresectable hepatocellular carcinoma (HCC). Methods Retrospective, cohort study of 51 patients treated with DEB‐TACE for unresectable HCC was studied: 23 with 100–300 μm particles and 28 with 70–150 μm particles. Overall, survival (OS), progression‐free survival (PFS), tumour response and prognostic factors were assessed. Results The median OS of the entire cohort was 30 months. The median OS and median PFS for 70–150 μm particles were not reached, whilst for the 100–300 μm group, it was 29.2 months and 15.0 months, respectively. The 6‐month, 1‐year and 2‐year OS for 70–150 μm was 96%, 86% and 85% versus the 100–300 μm particles size of 83%, 64% and 44%, respectively. At 1‐month follow‐up, patients treated with 70–150 μm had significantly better mRECIST tumour response compared to 100–300 μm (complete response 38.5% vs. 19%; partial response 57.7% vs. 42.9%; stable disease 0% vs. 4.8%; progressive disease 3.8% vs. 33.3%, P = 0.027). Patients treated with 100–300 μm DEBs were significantly more likely to have progressive disease on 1‐month follow‐up imaging compared those treated with 70–150 μm DEB sizes (odds ratio 7.15, P = 0.007). The 30‐day mortality rate was similar between the two groups (3.6% for 70–150 μm vs. 4.3% for 100–300 μm). Multivariate analysis demonstrated entire cohort OS was significantly associated with BCLC stage (aHR: 10.5, P = 0.002), albumin (aHR: 15.0, P = 0.02) and ALP (aHR 62, P = 0.001). Conclusions DEB‐TACE with 70–150 μm particles demonstrates improved 1‐month objective tumour response compared to 100–300 μm, whilst having a similar safety profile. Elevated ALP, lower albumin and higher BCLC stage were significantly associated with poorer survival outcomes.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival, tumour response and safety of 70‐150 μm versus 100‐300 μm doxorubicin drug‐eluting beads in transarterial chemoembolisation for hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In a recent study, 70-150 µm DEB-TACE achieved impressive objective response rates of 94.5% at 3 months, with a median overall survival of 42.0 months [13]. There are a few small retrospective studies that have compared the outcomes of 70-150 µm and 100-300 µm DEB-TACE [14][15][16][17]. However, since these studies have reported different results, it is difficult to confirm whether 70-150 µm DEB-TACE is superior to 100-300 µm DEB-TACE in terms of outcomes in patients with HCC.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Hong

Kim

et al. 2022

Life

View full text Add to dashboard Cite

Background: This study aimed to compare the efficacy and safety of 70–150 μm doxorubicin drug-eluting bead (DEB) transarterial chemoembolization (TACE) with those of 100–300 μm DEB-TACE as first-line treatment in patients with hepatocellular carcinoma (HCC). Methods: We retrospectively investigated 72 patients who underwent TACE with 70–150 μm DEBs (n = 40) or 100–300 μm DEBs (n = 32) for HCC in a tertiary center between March 2013 and May 2019. Initial treatment response and adverse events were assessed using the modified Response Evaluation Criteria in Solid Tumors and the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, respectively. Results: At the 2-month post-treatment assessment, the complete and objective response rates were 47.5% and 85.0%, respectively, for the 70–150 μm group and 34.4% and 81.3%, respectively, for the 100–300 μm group; however, the difference was not statistically significant (p > 0.05). In total, 65% patients in the 70–150 μm group and 59.4 % patients in the 100-300 μm group experienced at least one symptom of post-embolization syndrome after TACE; all symptoms were classified as grade 1 or 2. There was no significant difference between the two groups in terms of post-procedural laboratory changes such as changes in liver enzymes and bilirubin levels (p > 0.05). Laboratory toxicity of grade 3 occurred in three patients, all of which were transient elevation of liver enzyme levels. Hepatobiliary adverse events, such as bile duct injury, biloma, liver abscess, and hepatic infarction, were not observed in either treatment group. Conclusion: This study found no significant difference in tumor response between 70–150 μm and 100–300 μm DEB-TACE. Both groups showed favorable safety profiles, and the difference was not significant.

show abstract

Does size matter? A comparison of 70-150 μm (M1) versus 100-300 μm drug-eluting beads in transarterial chemoembolization for hepatic malignancy

Cited by 2 publications

References 0 publications

Survival, tumour response and safety of 70‐150 μm versus 100‐300 μm doxorubicin drug‐eluting beads in transarterial chemoembolisation for hepatocellular carcinoma

Survival, tumour response and safety of 70‐150 μm versus 100‐300 μm doxorubicin drug‐eluting beads in transarterial chemoembolisation for hepatocellular carcinoma

Comparison of Clinical Efficacy and Safety between 70–150 µm and 100–300 µm Doxorubicin Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Contact Info

Product

Resources

About